Can Mestinon be used to treat Postural Tachycardia Syndrome (POTS)?

Drugs.com

Official answer

by Drugs.com

Mestinon (pyridostigmine) has been used to treat postural tachycardia syndrome (POTS) and may improve symptoms such as a fast heart rate (tachycardia) and symptom burden (Raj et al., 2005). However, research that investigated the addition of Mestinon to standard beta-blocker treatment (propranolol or bisoprolol) found no additional advantage with the addition of Mestinon and suggested beta-blocker therapy alone to be the preferred option (Moon et al., 2018). Diarrhea is a common side effect of Mestinon that may limit its use for extended periods. The use of Mestinon for POTS is off-label (not an FDA-approved use).

Mestinon works by preventing the breakdown of acetylcholine, a nerve transmitter. A disturbance in the transmission of acetylcholine between ganglia is thought to cause the imbalance of the autonomic nervous system in POTS. Pyridostigmine increases parasympathetic nervous system activity and decreases heart rate in POTS. For more information about POTS see here.

Raj et al., 2005 performed a randomized crossover trial on 17 patients with POTS assigning them pyridostigmine (Mestinon) 30 mg orally and a placebo, on separate mornings. The patients’ heart rates were significantly lower 2 hours after pyridostigmine than after placebo (100+/-16 versus 111+/-14 bpm, P=0.001) and pyridostigmine significantly decreased the standing heart rate from baseline at 2 and 4 hours, and symptom burden at 4 hours. Blood pressure did not significantly change.

Moon et al., (2018) randomly assigned 103 POTS patients to one of 4 medical treatments (Group 1: propranolol; Group 2: bisoprolol; Group 3: propranolol+pyridostigmine (Mestinon); and Group 4: bisoprolol+pyridostigmine) for 3 months. Pyridostigmine was prescribed at a dose of 30 mg twice a day, which was maintained for 3 months. All treatments significantly improved orthostatic intolerance symptoms, symptoms of depression, and improved quality of life. Propranolol and bisoprolol demonstrated comparable therapeutic effects for POTS patients but additional pyridostigmine administration did not offer any additional benefits.

Related medical questions

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords